Plasminogen Activator Inhibitor-1-Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype
© 2022 The Authors..
Patients with established coronary artery disease remain at elevated risk of major adverse cardiac events. The goal of this study was to evaluate the utility of plasminogen activator inhibitor-1-positive platelet-derived extracellular vesicles as a biomarker for major adverse cardiac events and to explore potential underlying mechanisms. Our study suggests these extracellular vesicles as a potential biomarker to identify and a therapeutic target to ameliorate neointimal formation of high-risk patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
JACC. Basic to translational science - 7(2022), 10 vom: 01. Okt., Seite 985-997 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jung, Richard G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 08.11.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jacbts.2022.05.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348517912 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348517912 | ||
| 003 | DE-627 | ||
| 005 | 20231226040433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacbts.2022.05.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348517912 | ||
| 035 | |a (NLM)36337926 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jung, Richard G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasminogen Activator Inhibitor-1-Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.11.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. | ||
| 520 | |a Patients with established coronary artery disease remain at elevated risk of major adverse cardiac events. The goal of this study was to evaluate the utility of plasminogen activator inhibitor-1-positive platelet-derived extracellular vesicles as a biomarker for major adverse cardiac events and to explore potential underlying mechanisms. Our study suggests these extracellular vesicles as a potential biomarker to identify and a therapeutic target to ameliorate neointimal formation of high-risk patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CAD, coronary artery disease | |
| 650 | 4 | |a CMFDA, 5-chloromethylfluorescein diacetate | |
| 650 | 4 | |a DAPT, dual antiplatelet therapy | |
| 650 | 4 | |a DMSO, dimethyl sulfoxide | |
| 650 | 4 | |a EV, extracellular vesicle | |
| 650 | 4 | |a LRP1, low-density lipoprotein–related receptor-1 | |
| 650 | 4 | |a MACE, major adverse cardiac events | |
| 650 | 4 | |a PAI, plasminogen activator inhibitor | |
| 650 | 4 | |a PAI-1+ PEV, plasminogen activator inhibitor-1–positive platelet-derived extracellular vesicle | |
| 650 | 4 | |a PCI, percutaneous coronary intervention | |
| 650 | 4 | |a PEV, platelet-derived extracellular vesicle | |
| 650 | 4 | |a T-TAS, Total Thrombus-formation Analysis System | |
| 650 | 4 | |a VSMC, vascular smooth muscle cells | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a extracellular vesicles | |
| 650 | 4 | |a in-stent restenosis | |
| 650 | 4 | |a percutaneous coronary intervention | |
| 650 | 4 | |a plasminogen activator inhibitor-1 | |
| 650 | 4 | |a stent thrombosis | |
| 700 | 1 | |a Duchez, Anne-Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Simard, Trevor |e verfasserin |4 aut | |
| 700 | 1 | |a Dhaliwal, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Gillmore, Taylor |e verfasserin |4 aut | |
| 700 | 1 | |a Di Santo, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Labinaz, Alisha |e verfasserin |4 aut | |
| 700 | 1 | |a Ramirez, F Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Rasheed, Adil |e verfasserin |4 aut | |
| 700 | 1 | |a Robichaud, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Ouimet, Mireille |e verfasserin |4 aut | |
| 700 | 1 | |a Short, Spencer |e verfasserin |4 aut | |
| 700 | 1 | |a Clifford, Cole |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Fengxia |e verfasserin |4 aut | |
| 700 | 1 | |a Lordkipanidzé, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Burger, Dylan |e verfasserin |4 aut | |
| 700 | 1 | |a Gadde, Suresh |e verfasserin |4 aut | |
| 700 | 1 | |a Rayner, Katey J |e verfasserin |4 aut | |
| 700 | 1 | |a Hibbert, Benjamin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JACC. Basic to translational science |d 2016 |g 7(2022), 10 vom: 01. Okt., Seite 985-997 |w (DE-627)NLM258427175 |x 2452-302X |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:10 |g day:01 |g month:10 |g pages:985-997 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacbts.2022.05.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 10 |b 01 |c 10 |h 985-997 | ||